NASDAQ: IKNA - Ikena Oncology, Inc.

Yield per half year: -31.98%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Ikena Oncology, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Ikena Oncology, Inc.

Ikena Oncology, Inc. operates as an oncology company that develops precision medicines to biomarker-defined patients with specific unmet needs in the United States. Its lead oncology product candidate is IK-930, a paralog selective inhibitor of the transcriptional enhanced associate domain, a transcription factor in the Hippo signaling pathway. It also develops IK-595, designed to trap MEK and RAF for inhibiting RAS signals than existing inhibitors; and IK-175, a monotherapy and in combination with nivolumab in patients with advanced or metastatic solid tumors, including urothelial carcinomas.

more details
Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2021-03-26
ISIN US45175G1085
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://ikenaoncology.com
Цена ао 1.3
Change price per day: 0% (1.17)
Change price per week: +8.33% (1.08)
Change price per month: -12.69% (1.34)
Change price per 3 month: -22.52% (1.51)
Change price per half year: -31.98% (1.72)
Change price per year: -8.59% (1.28)
Change price per 3 year: -83.14% (6.94)
Change price per year to date: -27.33% (1.61)
All parameters

Underestimation

Title Value Grade
P/S 9.52 1
P/BV 0.6285 10
P/E 0 0
EV/EBITDA -0.8016 0
Total: 5.13

Efficiency

Title Value Grade
ROA, % -29.52 0
ROE, % -33.3 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.1275 10
Total: 9.8

Growth impulse

Title Value Grade
Yield Revenue, % -33.62 0
Yield Ebitda, % 33.42 5
Yield EPS, % -20.3 0
Total: 2
More

Institutions Volume Share, %
Orbimed Advisors LLC. 9907945 20.53
Atlas Venture Life Science Advisors, LLC 5018178 10.4
BVF Inc. 4769164 9.88
FMR, LLC 4184293 8.67
Omega Fund Management, Llc 2249123 4.66
Blue Owl Capital Holdings LP 1953616 4.05
Blackrock Inc. 1858156 3.85
Vanguard Group Inc 1524848 3.16
Verition Fund Management, LLC 1322397 2.74
Artal Group S.A. 999513 2.07



Head Job title Payment Year of birth
Dr. Mark Manfredi Ph.D. President, CEO & Director 810.69k 1971 (54 years)
Dr. Jotin Marango M.D., Ph.D. CFO & Head of Corporate Development 577.12k 1979 (46 years)
Mr. Bob Lally Senior Vice President of Finance & Operations N/A
Mr. Jeffrey Ecsedy Ph.D. Chief Development Officer N/A 1970 (55 years)
Mr. David Damphousse M.S. Senior Vice President of Clinical Development Operations N/A
Mr. Valdas Jurkauskas Ph.D. Senior Vice President of Technical Operations N/A
Dr. Caroline Germa M.D., Ph.D. Chief Medical Officer N/A 1972 (53 years)
Ms. Rebecca Cohen Vice President of Investor Relations, Corporate Strategy & Communication

Address: United States, Boston. MA, 645 Summer Street - open in Google maps, open in Yandex maps
Website: https://ikenaoncology.com